Wockhardt Share Price Jumps 9 Percent After Q4 FY26 PAT Swings to Rs 166 Crore from Year-Ago Loss

Wockhardt share price jumped approximately 9% on May 5, 2026, extending gains from the Q4 FY26 results declared on May 4, where the pharmaceutical company reported a consolidated net profit of Rs 166 crore versus a net loss of Rs 25 crore in Q4 FY25. The Wockhardt share price rally represents one of the most significant post-results moves for the pharma stock in recent years, with investors re-rating the company on the back of its ongoing business transformation driven by the novel antibiotic WCK pipeline and recovery in base pharmaceutical formulations business.

Total income for Q4 FY26 reached Rs 1,010 crore versus Rs 913 crore in Q3 FY26, while EPS for the quarter stood at Rs 10.22 versus Rs 3.61 in Q3 FY26. The Wockhardt share price movement reflects the scale of the quarterly improvement: the swing from a Rs 25 crore loss in Q4 FY25 to a Rs 166 crore profit in Q4 FY26 represents a Rs 191 crore year-on-year quarterly improvement, one of the largest PAT swings in Wockhardt’s recent listed history. FY26 overall business growth has been described as robust by the company.

Get Free Stock Recommendations on Univest

Wockhardt share price at a Glance

Track live stock data, analyst ratings and peer comparisons on the Univest Screener.

What Drove Wockhardt Share Price Jump After Q4 FY26 Results

The Wockhardt share price jump after Q4 FY26 results is explained by the combination of three positive developments in a single quarter. First, base pharmaceutical formulations business in regulated European markets including the UK and Germany showed recovery, contributing to the revenue growth. Second, early commercial traction from novel antibiotic products in the WCK series began generating revenue, adding a high-margin incremental income stream. Third, cost rationalisation across the organisation improved operating leverage, allowing more revenue to flow through to PAT. The Wockhardt share price had been depressed for years by the expectation that the WCK pipeline would take longer to commercialise; Q4 FY26 suggests commercialisation is underway.

WCK Novel Antibiotic Pipeline is the Long-Term Wockhardt Share Price Catalyst

The WCK series of novel antibiotics targeting drug-resistant bacterial infections is Wockhardt’s most valuable intellectual property and the primary long-term re-rating catalyst for the Wockhardt share price. Zaynich (cefepime-zidebactam) targets carbapenem-resistant bacterial infections, which represent a global healthcare crisis as bacteria develop resistance to existing antibiotics. Nafithromycin addresses macrolide-resistant respiratory infections. If these novel antibiotics receive regulatory approvals in major markets including the US FDA and EU EMA, Wockhardt would gain access to patent-protected, premium-priced antibiotic revenue streams that could be transformative for the Wockhardt share price long-term earnings profile.

Wockhardt Share Price and the Drug Resistant Bacteria Market Opportunity

The global antibiotic market for drug-resistant bacteria infections is valued at over $5 billion annually and growing. Wockhardt’s WCK antibiotics are specifically designed to be active against bacteria that have developed resistance to existing antibiotics, filling a critical unmet medical need. Regulatory designations like Qualified Infectious Disease Product (QIDP) and LPAD approval pathways in the US allow expedited review for novel antibiotics addressing unmet needs, which could accelerate the Wockhardt share price catalyst timeline from regulatory approvals. A major US FDA approval for Zaynich would be the single largest positive catalyst for Wockhardt share price in the company’s recent history.

Regulated Market Formulations Recovery Supporting Wockhardt Share Price

Beyond the WCK pipeline, Wockhardt’s base formulations business in the UK, Germany, and other European regulated markets has been recovering from the disruptions of prior years. The UK remains Wockhardt’s largest formulations market, with hospital-administered injectable products and oral solid dosage forms providing steady revenue streams. The Wockhardt share price at current levels benefits from this base formulations recovery providing an earnings floor even before any WCK novel antibiotic revenue contribution is factored in.

Wockhardt Share Price Outlook Post Q4 FY26 Results

Following the Q4 FY26 turnaround, the Wockhardt share price outlook for FY27 is positive. The base formulations recovery is expected to sustain, and any incremental novel antibiotic revenue from WCK series commercial expansions in European markets would add earnings upside. The key transformational catalyst for Wockhardt share price remains a US FDA approval for Zaynich or Nafithromycin, which would unlock US market access for the highest-value novel antibiotic sales. Investors should monitor the WCK regulatory filing status in the US and EU as the primary FY27 stock catalyst beyond the operational Q4 turnaround visible in current Wockhardt share price performance.

Download the Univest iOS App or Univest Android App for live market updates and expert research.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

Why did Wockhardt share price jump 9% on May 5, 2026?

Wockhardt share price jumped approximately 9% on May 5 after Q4 FY26 results showed PAT of Rs 166 crore versus a loss of Rs 25 crore in Q4 FY25. Total income reached Rs 1,010 crore and EPS stood at Rs 10.22. The Rs 191 crore year-on-year quarterly improvement reflected base formulations recovery in European markets and early commercial traction from the WCK novel antibiotic pipeline.

What is Wockhardt Q4 FY26 net profit?

Wockhardt Q4 FY26 consolidated PAT was Rs 166 crore, a dramatic turnaround from a loss of Rs 25 crore in Q4 FY25. This Rs 191 crore swing is one of the largest quarterly PAT improvements in Wockhardt’s recent history. Total income for Q4 FY26 was Rs 1,010 crore, up from Rs 913 crore in Q3 FY26.

What is the WCK novel antibiotic pipeline?

Wockhardt’s WCK pipeline includes Zaynich (cefepime-zidebactam) targeting carbapenem-resistant bacteria and Nafithromycin addressing macrolide-resistant respiratory infections. These novel antibiotics address drug-resistant bacteria representing a global healthcare crisis. US FDA and EU EMA regulatory approvals for these products would be the single largest transformational catalysts for Wockhardt share price.

Is Wockhardt a good investment after Q4 FY26 results?

Wockhardt share price has rallied sharply post Q4 turnaround. The base formulations recovery provides near-term earnings support, while the WCK pipeline provides transformational long-term upside on regulatory approvals. Risks include potential delays in WCK approvals and competitive pressures in European formulations markets. Consult a SEBI-registered financial advisor before making investment decisions.

Recent Article

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026

Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026

Why Is PSP Projects Share Price Falling Key Reasons 2026